#Cellectis (CLLS) - Prohost Biotech

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

bluebird bio Suspends LentiGlobin Studies bluebird bio ( BLUE ) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a tem...

P

Prohost Biotech

Feb 17, 2021

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

Gilead Sciences News Results from Phase 2/3 CAPELLA trial evaluating Gilead Sciences ( GILD ) lenacapavir achieved the primary endpoint in heavily treatment-experienced people with multidrug-resistan...

P

Prohost Biotech

Nov 19, 2020

Prohost Letter #438 ~ The End of the Year Issue 2019

Prohost Letter #438 End of the Year Issue 2019 Happy New Year 2020 The NASDAQ reached 9000 for the first time in the market history on December 30, 2019. However, on the last trading day of 2019, the...

P

Prohost Biotech

Jan 1, 2020

The Week in Review #48 ~ Holiday Edition

The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You a Happy New Year Filled with Excellent Health, Peace of Mind, Prosperity and Happiness What...

P

Prohost Biotech

Dec 27, 2019

1m

21

News & Comments

Gilead's CAR T Product Yescarta Demonstrates Positive Survival Results

Gilead's CAR-T Product Yescarta Results Kite, a Gilead (GILD) subsidiary, announced new data from the ZUMA-1 trial of the CAR T Yescarta (axicabtagene ciloleucel) in adult patients with refractory lar...

P

Prohost Biotech

Dec 8, 2019

Let the Market Plummet But Not Our stocks

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally...

P

Prohost Biotech

Dec 3, 2019

Small firms developing improved CAR T immunotherapy products.

We have a few small clinical stage firms in the Prohost Portfolio that were established with the goal of designing safer and more effective versions of the very promising CAR T immuno-oncology produc...

P

Prohost Biotech

Dec 28, 2018

When common sense fails to explain market performance

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual for the stock market to be in a selloff mood for a few days . However, in the last couple of months, the...

P

Prohost Biotech

Dec 3, 2018

Immunotherapy and some other results from ESMO 2018

IMMUNOTHERAPY The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on the surface of the immune system cells. The checkpoint proteins ’ natural job is to put...

P

Prohost Biotech

Oct 24, 2018

Following the Stars. Less Science and More Logic

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a human star is born every once in a while on Earth, several stars born daily in research labs may be design...

P

Prohost Biotech

Oct 14, 2018

Victims of fear and misunderstanding

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical firms, analysts currently rely for their assessment on criteria that include qua...

P

Prohost Biotech

Aug 1, 2018

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its...

P

Prohost Biotech

Jul 9, 2018

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

The Week in Review #21 Part 2 THE MARKET (2) - Our remarks in the past Week in Review included our confidence that the attempts by negative investors to drive the market crazy will not deprive the ma...

P

Prohost Biotech

Apr 30, 2018

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If They Sell the Best of the Best Biotechnology Firms Only Because the Market Is Weird Even if one is scared...

P

Prohost Biotech

Apr 5, 2018

Highlighting Gene Editing Firms

The Week in Review #19 Targeting the Root-Cause of Diseases - Investing in the Future is Currently the Best Way - Stopping aberrant genes from causing diseases has taken time to move from wishful thi...

P

Prohost Biotech

Mar 12, 2018

Private Lessons and More

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this homework before we go into further evaluations of our picks and introduction of new companies as we promised in th...

P

Prohost Biotech

Feb 9, 2018

1m

16

News & Comments

Cellectis: Offering Proof of Concept is What Led to the Stock Rally

UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes the difference between Cellectis’ CAR T products and the two...

P

Prohost Biotech

Dec 14, 2017

Gilead's New Acquisition: An Important Step Forward Toward Building a Superior Cancer Franchise

Gilead Sciences (GILD ) has unsurprisingly agreed to acquire Cell Design Labs in a structured buy out valued for up to $567 million, including the shares of Cell Design Labs held by Kite, the CAR T fi...

P

Prohost Biotech

Dec 8, 2017

1m

20

News & Comments

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric rec...

P

Prohost Biotech

Nov 21, 2017

The Week in Review #11

The Week in Review #11 A New Era - Faster than the speed of light, the management of diseases is shifting from fast improvement to a total gigantic unprecedented change. Some of the conquering approac...

P

Prohost Biotech

Nov 20, 2017

1m

16